RxDoctor Payments Data

Linus Ema, DO

Internal Medicine · Chicago, ILNPI 1891728010

Payments from drug & device makers

$596in general payments, 2019–2025

Across 32 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$212
  • AstraZeneca$142
  • Pfizer$105
  • Lilly USA, LLC$67
  • Edwards Lifesciences$50
  • GSK$20

What the payments were for

  • Food & beverage$58498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$212
AstraZeneca9$142
Pfizer5$105
Lilly USA, LLC3$67
Edwards Lifesciences3$50
GSK1$20

How this compares

$596 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$54,346
Medicare patients
121
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$84,756
RybelsusSemaglutide54$71,213
EliquisApixaban69$62,026
OzempicSemaglutide33$51,686
XareltoRivaroxaban19$27,969
TrulicityDulaglutide23$20,929
MounjaroTirzepatide11$11,829
FarxigaDapagliflozin Propanediol13$11,102
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,550
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$6,469
NamzaricMemantine Hcl/Donepezil Hcl16$5,720
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,241
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,984
Potassium Chloride214$4,208
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$212$122,90087 claims
PfizerEliquis$105$62,02669 claims
Lilly USA, LLCTrulicity, Mounjaro$67$32,75834 claims
AstraZenecaFarxiga$142$11,10213 claims
GSKAnoro Ellipta$20$6,55013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →